New York, New York--(Newsfile Corp. - February 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations during the class period [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of critical information regarding stock price manipulation [5].

Core Points - Rosen Law Firm is reminding purchasers of CoreWeave, Inc. securities from March 28, 2025, to December 15, 2025, about the lead plaintiff deadline on March 13, 2026 [1] - Investors who purchased CoreWeave securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Class Action Details - A class action lawsuit has been filed against CoreWeave, alleging that the company made false and misleading statements regarding its ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [4] - The lawsuit claims that these misstatements were likely to have a material negative impact on CoreWeave's revenue, leading to investor damages when the true information became public [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 and being ranked No. 1 for securities class action settlements in 2017 [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ramaco Resources, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ramaco securities between July 31, 2025, and October 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 31, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding the mining activities at the Brook Mine, claiming that significant work had not commenced despite positive statements about Ramaco's business and operations [5]. - The lawsuit claims that the lack of actual mining activity led to an overstatement of development progress, resulting in misleading information provided to investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and securing over $438 million for investors in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Inovio securities between October 10, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that these misrepresentations caused investors to suffer damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit has been filed against PomDoctor Ltd. for misleading statements and fraudulent activities during the Class Period from October 9, 2025, to December 11, 2025 [4] - Investors who purchased PomDoctor securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, and a lead plaintiff acts on behalf of other class members [2] Group 2: Allegations Against PomDoctor - The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [4] - It is claimed that insiders used offshore accounts to facilitate the coordinated dumping of shares during a price inflation campaign [4] - The public statements made by PomDoctor omitted critical information regarding false rumors and artificial trading activity that influenced the stock price [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly providing misleading information regarding its financial targets and growth potential during the specified Class Period from February 25, 2025, to February 2, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that PayPal's management provided overly optimistic statements about the company's growth potential and its ability to execute on new initiatives, while concealing material adverse facts about the salesforce's readiness [5]. - Investors who purchased PayPal common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - Investors interested in joining the class action can do so by submitting a form or contacting the firm directly [3][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities between October 9, 2025, and December 11, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PomDoctor securities during the specified period may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff representing other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that PomDoctor made false or misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and insider trading activities [4]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that PomDoctor's public statements omitted mention of false rumors and artificial trading activity [4]. - As a result of these actions, the positive statements made by PomDoctor regarding its business and prospects were materially misleading [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BellRing Brands, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought BellRing securities between November 19, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 23, 2026 [3]. Group 2: Case Background - BellRing Brands develops and sells "convenient nutrition" products, primarily under the Premier Protein brand, including ready-to-drink protein shakes [5]. - The lawsuit alleges that BellRing misrepresented sales growth as being driven by consumer demand, while in reality, it was due to key customers stockpiling inventory, leading to a misrepresentation of the company's market position [5]. - Following a period of destocking, BellRing acknowledged that competitive pressures were negatively impacting demand, which contradicted earlier claims made by the company [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bath & Body Works, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Bath & Body Works securities between June 4, 2024, and November 19, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit alleges that Bath & Body Works made materially false and misleading statements regarding its business strategy and financial performance, which led to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4].